Cellectis (CLLS) EBIT Growth (3y) (2018 - 2026)

Cellectis (CLLS) EBIT Growth (3y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 16.96%
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 38.78%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -12.10%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Cellectis 281.48 Mn 95.81 Mn - -2.41%

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.41%
Dec 31, 2025 -45.27%
Sep 30, 2025 31.89%
Jun 30, 2025 29.46%
Mar 31, 2025 21.43%
Dec 31, 2024 24.24%
Sep 30, 2024 36.65%
Jun 30, 2024 22.85%
Mar 31, 2024 -1.63%
Dec 31, 2023 8.93%
Sep 30, 2023 11.03%
Jun 30, 2023 10.58%
Mar 31, 2023 -53.63%
Dec 31, 2022 47.22%
Sep 30, 2022 -0.87%
Jun 30, 2022 8.04%
Mar 31, 2022 -8.13%
Dec 31, 2021 5.68%
Sep 30, 2021 -13.60%
Jun 30, 2021 -19.99%